Passa al contenuto
Merck
Tutte le immagini(1)

Documenti fondamentali

860547P

Avanti

C18 Glucosyl(β) Ceramide (d18:1/18:0)

Avanti Research - A Croda Brand

Sinonimo/i:

D-glucosyl-β-1,1′-N-stearoyl-D-erythro-sphingosine

Autenticatiper visualizzare i prezzi riservati alla tua organizzazione & contrattuali

Scegli un formato

5 MG
261,00 €

261,00 €


Per informazioni sulla disponibilità, contatta il Servizio Clienti.

Richiedi un ordine bulk

Scegli un formato

Cambia visualizzazione
5 MG
261,00 €

About This Item

Formula empirica (notazione di Hill):
C42H81NO8
Numero CAS:
Peso molecolare:
728.09
Codice UNSPSC:
12352211
NACRES:
NA.25

261,00 €


Per informazioni sulla disponibilità, contatta il Servizio Clienti.

Richiedi un ordine bulk

Stato

powder

Confezionamento

pkg of 1 × 100 mg (860547P-100mg)
pkg of 1 × 25 mg (860547P-25mg)
pkg of 1 × 5 mg (860547P-5mg)

Produttore/marchio commerciale

Avanti Research - A Croda Brand

Tipo di lipide

sphingolipids

Condizioni di spedizione

dry ice

Temperatura di conservazione

−20°C

Stringa SMILE

[H][C@](/C=C/CCCCCCCCCCCCC)(O)[C@@]([H])(NC(CCCCCCCCCCCCCCCCC)=O)CO[C@H](O1)[C@H](O)[C@@H](O)[C@@H]([C@H]1CO)O

InChI

1S/C42H81NO8/c1-3-5-7-9-11-13-15-17-18-20-22-24-26-28-30-32-38(46)43-35(34-50-42-41(49)40(48)39(47)37(33-44)51-42)36(45)31-29-27-25-23-21-19-16-14-12-10-8-6-4-2/h29,31,35-37,39-42,44-45,47-49H,3-28,30,32-34H2,1-2H3,(H,43,46)/b31-29+/t35-,36+,37?,39+,40?,41?,42+/m0/s1
YMYQEDCYNANIPI-KNSMPFANSA-N

Applicazioni

C18 Glucosyl(β) Ceramide (d18:1/18:0) or D-glucosyl-β-1,1′-N-stearoyl-D-erythro-sphingosine has been used:
  • as a lipid standard for its quantification using differential ion mobility spectrometry (DMS) coupled with liquid chromatography in electrospray ionization tandem mass spectrometry (LC-ESI-DMS-MS/MS) in human plasma[1]
  • in the preparation of lipid dispersions[2]
  • used in an assay to monitor the turnover of glucosylceramide in glucocerebrosidase (GBA1) cell free system[3]

Confezionamento

5 mL Amber Glass Screw Cap Vial (860547P-100mg)
5 mL Amber Glass Screw Cap Vial (860547P-25mg)
5 mL Amber Glass Screw Cap Vial (860547P-5mg)

Note legali

Avanti Research is a trademark of Avanti Polar Lipids, LLC

Codice della classe di stoccaggio

11 - Combustible Solids


Scegli una delle versioni più recenti:

Certificati d'analisi (COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our Documenti section.

Se ti serve aiuto, non esitare a contattarci Servizio Clienti

Possiedi già questo prodotto?

I documenti relativi ai prodotti acquistati recentemente sono disponibili nell’Archivio dei documenti.

Visita l’Archivio dei documenti

I clienti hanno visto anche

Jong Hoon Won et al.
Neuroscience, 427, 1-15 (2019-11-26)
Neurotransmitter release is mediated by ceramide, which is generated by sphingomyelin hydrolysis. In the present study, we examined whether synaptosomal-associated protein 25 (SNAP-25) is involved in ceramide production and exocytosis. Neutral sphingomyelinase 2 (nSMase2) was partially purified from bovine brain
Hongbin Xu et al.
Journal of lipid research, 60(1), 200-211 (2018-11-11)
Cerebrosides, including glucosylceramides (GlcCers) and galactosylceramides (GalCers), are important membrane components of animal cells with deficiencies resulting in devastating lysosomal storage disorders. Their quantification is essential for disease diagnosis and a better understanding of disease mechanisms. The simultaneous quantification of
Differential mobility spectrometry as an orthogonal separation to LC-ESI-MS/MS for quantification of isomeric cerebrosides in plasma and cerebrospinal fluid
Xu H, et al.
Journal of Lipid Research, jlr-D089797 (2018)
Joseph R Mazzulli et al.
Cell, 146(1), 37-52 (2011-06-28)
Parkinson's disease (PD), an adult neurodegenerative disorder, has been clinically linked to the lysosomal storage disorder Gaucher disease (GD), but the mechanistic connection is not known. Here, we show that functional loss of GD-linked glucocerebrosidase (GCase) in primary cultures or
Victoria Schiffer et al.
PloS one, 15(1), e0227077-e0227077 (2020-01-14)
Gaucher disease is caused by a deficiency in glucocerebrosidase that can result in non-neuronal as well as neuronal symptoms. Common visceral symptoms are an increased organ size, specifically of the spleen, and glucosylceramide as well as glucosylsphingosine substrate accumulations as

Il team dei nostri ricercatori vanta grande esperienza in tutte le aree della ricerca quali Life Science, scienza dei materiali, sintesi chimica, cromatografia, discipline analitiche, ecc..

Contatta l'Assistenza Tecnica.